825 related articles for article (PubMed ID: 10080595)
21. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathological features and prognosis of renal cell carcinoma with sarcomatoid differentiation].
Jiang Y; Su G; Yu W; Li J; Lu Q; Li Y; Zhang W
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):823-6. PubMed ID: 26887511
[TBL] [Abstract][Full Text] [Related]
24. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
[TBL] [Abstract][Full Text] [Related]
25. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
Rini BI; Shaw V; Rosenberg JE; Kim ST; Chen I
Clin Genitourin Cancer; 2006 Dec; 5(3):232-4. PubMed ID: 17239278
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
27. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
28. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
29. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
Brinkmann OA; Bruns F; Prott FJ; Hertle L
Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
[TBL] [Abstract][Full Text] [Related]
30. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
31. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
32. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.
Mian BM; Bhadkamkar N; Slaton JW; Pisters PW; Daliani D; Swanson DA; Pisters LL
J Urol; 2002 Jan; 167(1):65-70. PubMed ID: 11743277
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy using tumor-infiltrating lymphocytes.
Figlin RA
Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
[No Abstract] [Full Text] [Related]
35. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
[TBL] [Abstract][Full Text] [Related]
36. Abundant CD8+ tumor infiltrating lymphocytes and beta-2-microglobulin are associated with better outcome and response to interleukin-2 therapy in advanced stage clear cell renal cell carcinoma.
Davis D; Tretiakova MS; Kizzar C; Woltjer R; Krajbich V; Tykodi SS; Lanciault C; Andeen NK
Ann Diagn Pathol; 2020 Aug; 47():151537. PubMed ID: 32454441
[TBL] [Abstract][Full Text] [Related]
37. Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report.
Yaegashi H; Izumi K; Konaka H; Mizokami A; Namiki M
J Med Case Rep; 2015 Nov; 9():261. PubMed ID: 26582158
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2008 Feb; 23(1):129-34. PubMed ID: 18298337
[TBL] [Abstract][Full Text] [Related]
39. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]